Regencell Bioscience (NASDAQ:RGC) Sees Strong Trading Volume – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) saw unusually-high trading volume on Monday . Approximately 776,339 shares changed hands during trading, an increase of 84% from the previous session’s volume of 422,906 shares.The stock last traded at $25.37 and had previously closed at $20.54.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Regencell Bioscience Trading Up 60.1%

The stock has a 50 day moving average of $17.39 and a 200-day moving average of $16.15.

Institutional Investors Weigh In On Regencell Bioscience

Large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience in the second quarter valued at approximately $1,701,000. Geode Capital Management LLC raised its position in shares of Regencell Bioscience by 5,637.5% in the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after purchasing an additional 384,250 shares during the last quarter. Greenfield Savings Bank acquired a new stake in Regencell Bioscience in the 2nd quarter worth approximately $187,000. Y Intercept Hong Kong Ltd purchased a new stake in Regencell Bioscience during the 2nd quarter worth approximately $222,000. Finally, XTX Topco Ltd acquired a new position in Regencell Bioscience during the 3rd quarter valued at approximately $598,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.